Get 3.3% from Extendicare

This company represents one of the most compelling investment opportunities in Canada’s healthcare sector. It’s well-positioned to capitalize on powerful demographic and industry changes. The company’s strategic transformation into a diversified senior care provider also strengthens its competitive advantage.

Demographically, Canada’s population aged 85 and older is projected to double by 2036 and triple by 2051. That creates an unprecedented demand for the company’s services.

Meanwhile, the stock trades at a reasonable 18.5 times the company’s forward earnings forecast.

EXTENDICARE INC. (Toronto symbol EXE; www.extendicare.com) owns and operates long-term care homes. Investors also tap the company’s ParaMed Home Health Care branches. ParaMed provides nursing care and other forms of assistance to clients who remain in their own homes.

Extendicare delivered exceptional performance in the second quarter ended June 30, 2025. In fact, it demonstrated robust year-over-year growth across all key financial metrics compared to the same quarter in 2024. The company generated $383.4 million in revenue, representing a solid 10.0% increase from $348.5 million a year earlier. This growth was driven primarily by strategic acquisitions and strong performance in the home health care segment.

Net income reached $31.9 million in 2025, marking an impressive 23.3% increase from $25.9 million. Earnings per share expanded even more dramatically, rising 26.7% to $0.38 from $0.30. That reflects both improved profitability and the company’s share buybacks. Meanwhile, operating cash flow grew substantially by 19.9%, to $52.9 million from $44.2 million a year earlier. Free cash flow increased 12.4% to $39.0 million.

[ofie_ad]

Dividend Stocks: Acquisitions create a dominant integrated care provider

The company completed two transformative acquisitions during the quarter. In June, Extendicare acquired nine long-term care homes from Revera for $41.9 million, adding 822 LTC beds and 574 private pay retirement beds to its portfolio. This transaction is expected to contribute approximately $109.3 million in annual revenue and $6.8 million in net operating income.

The ParaMed unit has also completed its acquisition of Closing the Gap Healthcare Group Inc. and certain affiliates. The purchase price was $75.5 million, but the transaction costs may ultimately be higher depending on whether the business achieves certain targets.

Founded in 1990, Closing the Gap is a leading provider of integrated home and community-based healthcare services in Ontario and Nova Scotia. It delivers adult and pediatric care services in patients’ homes and in community clinics.

In addition to personal support and nursing services, Closing the Gap has expertise in allied health services, including physiotherapy, occupational therapy, speech language pathology, nutrition and social work.

Based on Closing the Gap’s 2024 financial performance, its acquisition should add roughly $84.2 million in revenue to Extendicare’s home health care segment; its profit margins are very similar to those of Extendicare’s ParaMed.

With monthly dividends of $0.042 per share, Extendicare provides an attractive 3.3% yield. The dividend payout is sustainable, representing a healthy 33.2% of earnings.

Extendicare trades at 18.5 times its forecast earnings. That multiple is attractive relative to many of the company’s North American competitors.

Recommendation in Dividend Advisor: Extendicare Inc. is a buy.

Jim is an associate editor at TSI Network. He is the lead reporter and analyst for The Successful Investor and Wall Street Stock Forecaster and a member of the Investment Planning Committee. Jim has held the Chartered Financial Analyst designation since 1992 and spent more than a decade at the Financial Post DataGroup before joining TSI Network. He has a Bachelor of Commerce degree from the University of Toronto.